Press Resease

Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis

Non-Invasive Prenatal Testing (NIPT) Market By Test Type (Panel 1, Panel 2 And Panel 3) And End-Users (Hospitals, Diagnostic Centers And Maternity Clinics): Global Industry Perspective, Comprehensive Analysis And Forecast, 2020 – 2028

Published Date: 05-Jul-2021 Category: Pharmaceutical Report Format : PDF Pages: 130 Report Code: ZMR-2512 Status : Published

The global Non-Invasive Prenatal Testing (NIPT) market accounted for USD 921 Million in 2020 and is expected to reach USD 1582 Million by 2028, growing at a CAGR of around 6.7% between 2021 and 2028.

Description

Market Overview     

The global Non-Invasive Prenatal Testing (NIPT) market accounted for USD 921 Million in 2020 and is expected to reach USD 1582 Million by 2028, growing at a CAGR of around 6.7% between 2021 and 2028.

Non-invasive prenatal testing is a complicated technology that helps determine fetal chromosomal anomalies by analyzing the fetus's cell-free DNA. because the invasive procedures have a better risk quotient, including the danger of fetal loss, most healthcare professionals prefer non-invasive techniques. NIPTs are new genetic tests that use cell-free circulating fetal DNA within the maternal serum to screen for more common fetal aneuploidies, like mongolism, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). With increased patient access to healthcare information also as advertising, the NIPT market is anticipated to possess a positive outlook within the coming years.

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic rise in the demand for healthcare facilities across the world. 2020 has been a dramatic rush of hospital visits and checkups so far, all because of a pandemic that has shaken the entire world. The Novel Coronavirus that caused the COVID-19 disease unleashed a disaster of extraordinary proportions. As healthcare spends for COVID-19 increases exponentially, companies that conduct research, develop potential vaccines, produce test kits, and manufacture or supply medical equipment are likely to benefit the most. The reason is clear - governments across the world will invest in not only damage control, but also in the prevention of any potential resurgence of the pandemic. This also means that companies other than those manufacturing types of equipment or infrastructure support that are not directly connected to COVID-19 would face disruptions in business.

Growth Factors

 Advantages offered by NIPT like non-invasiveness, high accuracy, and early detection, raising awareness, increasing penetration in highly untapped countries in Asia and Latin America, and continuous increase in average maternal age are the main factors expected to drive the expansion of the worldwide NIPT market during the forecast period. However, the market is additionally facing significant ethical and regulatory hurdles related to the implementation of NIPT due to the assumption that it's likely to extend the incidence of abortions. Therefore, various professional organizations like the American College of Obstetricians and Gynecologists (ACOG), the International Society for a diagnostic procedure, the Japan Society of Obstetrics and Gynecology, and genetic counselors across the planet have found out guidelines that limit the utilization of non-invasive prenatal testing only to pregnant women at high risk of chromosomal aneuploidies.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

Based on test type the market is segmented into panel 1, panel 2 and panel 3. Based on end-user, the worldwide marketplace for OR equipment is segmented into hospitals, diagnostic centers, and maternity clinics. Diagnostic centers have accounted for the main share of this segment in 2018 due to the increased investments in healthcare infrastructure & the use of advanced technologies. The increasing incidence of chromosomal abnormalities coupled with growing product usage in new applications is driving the organic revenue growth in the market. Additionally, increasing demand for patient satisfaction, cost-effective procedures, and efficient practices by healthcare professionals also are expected to spice up the expansion of this market within the forecast period.

Regional Analysis Preview

Based on geography, North America held the most important share of the worldwide NIPT market in terms of revenue. Major players domiciled within the U.S. and comparatively high awareness levels about NIPT in North America are the key factors attributed to the region’s leadership position. In Europe, market growth largely depends upon the increasing penetration of those U.S.-based test developers and an increase in acceptance of those tests. Japan, Australia, China, and India represent high growth potential markets in Asia-Pacific. The NIPT market in China is dominated by two local players BGI Diagnostics and Berry Genomics. Additionally, the recent CFDA approval for Bambini Test would propel the expansion of the market during this region.

Key Market Players & Competitive Landscape

The major players that are comprised in  Non-Invasive Prenatal Testing (NIPT) market are Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc. The market is saturated with few players operating in the NIPT space and these companies are expected to compete on the grounds of cost and functionality. Product differentiation, new product launches and merger and acquisition are some of the strategies adopted by these industry participants. 

The global  Non-Invasive Prenatal Testing (NIPT) Market is segmented as follows:

By Test Type

  • Panel 1
  • Panel 2
  • Panel 3

By End-User

  • Hospitals
  • Diagnostic Centers
  • Maternity Clinics

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Test Type
        • 2.1.1.2. Market Attractiveness Analysis, By End-User
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Non-Invasive Prenatal Testing (NIPT) Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Non-Invasive Prenatal Testing (NIPT) Market – Test Type Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Test Type, 2020 & 2028
    • 4.2. Panel 1
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. PANEL 2
      • 4.3.1. Market Size and Forecast, By Region (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Panel 3
      • 4.4.1. Market Size and Forecast, By Region (USD Million)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Non-Invasive Prenatal Testing (NIPT) Market – End User Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By End-User, 2020 & 2028
    • 5.2. Hospitals
      • 5.2.1. Market Size and Forecast, By Region (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Diagnostic Centers
      • 5.3.1. Market Size and Forecast, By Region (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Maternity Clinics
      • 5.4.1. Market Size and Forecast, By Region (USD Million)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Non-Invasive Prenatal Testing (NIPT) Market – Region Segment Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.2.2. North America Market Revenue, By Test Type, 2016 – 2028
      • 6.2.3. North America Market Revenue, By End-User, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Test Type, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By End-User, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Test Type, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By End-User, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Test Type, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By End-User, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.3.2. Europe Market Revenue, By Test Type, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By End-User, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Test Type, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By End-User, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Test Type, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By End-User, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Test Type, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By End-User, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Test Type, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By End-User, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Test Type, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By End-User, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Test Type, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By End-User, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.4.2. Asia Pacific Market Revenue, By Test Type, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By End-User, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Test Type, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By End-User, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Test Type, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By End-User, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Test Type, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By End-User, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Test Type, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By End-User, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Test Type, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By End-User, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Test Type, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By End-User, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.5.2. Latin America Market Revenue, By Test Type, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By End-User, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Test Type, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By End-User, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Test Type, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By End-User, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Test Type, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By End-User, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Test Type, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By End-User, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Test Type, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By End-User, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Test Type, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By End-User, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Test Type, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By End-User, 2016 – 2028
  • Chapter No. 7: Non-Invasive Prenatal Testing (NIPT) Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. By End-User Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Non-Invasive Prenatal Testing (NIPT) Market: Company Market Share, 2019
      • 8.1.2. Global Non-Invasive Prenatal Testing (NIPT) Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 8.1.3. Global Non-Invasive Prenatal Testing (NIPT) Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Non-Invasive Prenatal Testing (NIPT) Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Ariosa Diagnostics, Inc.
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfulio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Genesis Genetics (CooperSurgical, Inc.)
    • 9.3. Natera, Inc.
    • 9.4. Centogene N.V.
    • 9.5. Illumina, Inc. (Verinata Health, Inc.)
    • 9.6. Eurofins LifeCodexx GmbH
    • 9.7. MedGenome Labs Ltd.
    • 9.8. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
    • 9.9. Myriad Women’s Health, Inc. (Myriad Genetics Inc/Counsyl, Inc.)
    • 9.10. Progenity, Inc.
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodulogy
    • 11.1. Research Methodulogy
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Non-Invasive Prenatal Testing market. Zion Research has collected and analyzed key data belong to the global Non-Invasive Prenatal Testing market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Non-Invasive Prenatal Testing across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Non-Invasive Prenatal Testing industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Non-Invasive Prenatal Testing market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Prenatal screening and diagnosis involve testing for conditions in a fetus before it is born, with the aim of detecting causes of birth defects, abnormalities, and genetic conditions. Advancing the prenatal care services provided across the globe has become an uphill battle for medical practitioners and drug makers. Fortunately, this struggle is being eased by the active participation of parents from all around the world in protecting the health of their soon-to-be-born babies through prenatal disease detection methods. Noninvasive prenatal testing (NIPT) procedures are, hence, being rapidly adopted, which is prompting healthcare service providers to increase their focus on such prenatal diagnosis & screening services. Application of the technique to analyze approximately 20,000 genetic features in a single reaction in a sensitive and accurate manner for detection of a wide range of genetic disorders with fewer false positives is expected to propel the demand for NIPT products in the coming years.

The vendors are increasingly entering into partnerships and collaborations to extend their product offerings, increase their market shares, and expand their operations. These partnerships and collaborations help vendors enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. For instance, in 2015, Human Longevity entered into collaboration with Roche Diagnostics to conduct whole-genome sequencing of Roche Diagnostics' subsidiary Genentech's de-identified samples. The partnership helped Roche Diagnostics analyze patient samples based on precise genetic categories and discover new diagnostics and targeted therapies. These partnerships and collaborative activities are accelerating drug discovery efforts, which will lead to the development of new therapies to detect chromosomal abnormalities in neonates. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

-Non-Invasive-Prenatal-Testing-(NIPT)-Market.png

Based on test type, the non-invasive prenatal testing market is been segmented into panel 1, panel 2 and panel 3 tests. Based on end-user the non-invasive prenatal testing market is segmented into hospitals, diagnostic centers, and maternity clinics.

The global NIPT market is highly fragmented owing to the presence of several well-established global and regional vendors. The majority of vendors are looking to expand their businesses in the APAC region, which is a major untapped market that is likely to grow at a rapid pace during the forecast period. To increase the adoption of new non-invasive tests, many companies focus on developing and strengthening their research infrastructure to develop efficient NIPTs. The competitive environment in this market is expected to intensify with an increase in product/service extensions, technological innovations, and mergers and acquisitions.

Some of the key players in the non-invasive prenatal testing market include Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc. The participants are engaged in the development and licensing of the software and cloud-based distribution model to enhance technology transfer. For instance, Natera underwent a licensing agreement with Unilab, which enables Unilab to access the proprietary protocols and key technology of Natera, thus driving revenue share of the company in reproductive genetic testing.


Frequently Asked Questions

The global  Non-Invasive Prenatal Testing (NIPT) Market was valued at USD 921 Million in 2020.

The global  Non-Invasive Prenatal Testing (NIPT) Market is expected to reach USD 1582 Million by 2028, growing at a CAGR of 6.7% between 2021 to 2028.

The increasing incidence of chromosomal abnormalities coupled with growing product usage in new applications is driving the organic revenue growth in the market.

North America in 2020 ruled the  Non-Invasive Prenatal Testing (NIPT) market and was believed to be the highest income-generating area all over the globe.  

The major players that are comprised in Non-Invasive Prenatal Testing (NIPT) market are Ariosa Diagnostics, Inc., Berry Genomics Co., Ltd, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom Laboratories, and Quest Diagnostics, Inc.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social